Physician profile
Michael Wayne Farwell
NPI 1508246935
$7,380.96
in general payments reported to CMS, 2019-2025
41 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.23 · 2021: $17.42 · 2022: $1,009 · 2023: $1,433 · 2024: $2,638 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,261.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $835.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $811.21 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $704.77 | 2022-2025 | |
| Lilly USA, LLC | $513.44 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Ucb, INC. | $507.31 | 2023-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $441.14 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $433.50 | 2022-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Amgen INC. | $340.89 | 2022-2025 | Evenity, Otezla, Tavneos |
| Bausch Health US, LLC | $291.12 | 2022-2025 | Aplenzin, Wellbutrin |
| Abbott Laboratories | $278.41 | 2022-2025 | Freestyle Libre 3, Eterna |
| Sumitomo Pharma America, INC. | $248.67 | 2023-2025 | Gemtesa |
| Pfizer INC. | $210.91 | 2022-2025 | |
| Exact Sciences Corporation | $200.60 | 2023-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $127.61 | 2023-2025 | Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $123.50 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Farwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.